Suppr超能文献

两种肾移植冲洗及保存液在移植后移植肾功能延迟风险和成本方面的比较研究

Comparative study on two kidney graft rinsing and preservation solutions in terms of the post-transplantation risk of delayed graft function and cost.

作者信息

Vincentelli J, Luccioni A, Devictor B, Dussol B, Lechevallier E, Bertault-Peres P, Coulange C, Berland Y, Penot Ragon C

机构信息

Department of Pharmacy, Department of Renal Transplantation, CHU-Sud, Public Health Service, Université de la Méditerranée, Marseille, France.

出版信息

J Clin Pharm Ther. 2003 Aug;28(4):273-7. doi: 10.1046/j.1365-2710.2003.00489.x.

Abstract

OBJECTIVE

To determine whether Belzer solution (Viaspan, Bristol-Myers Squibb, Brussels, Belgium), which is more expensive than Eurocollins solution, was better at preventing delayed graft function (DGF) and whether it was cost-effective as it could potentially reduce post-transplantation complications.

METHOD

The risk of occurrence of complications associated with the use of these two rinsing and preserving solutions was estimated from a survey of 106 patients undergoing renal transplantation between 1 January 1993 and 31 March 1998. Both efficacy and adverse outcomes were recorded along with the costs directly associated with the transplantation procedure in the hospital setting: hospitalization, rinsing and preserving solutions, medical and technical interventions and diagnostic tests.

RESULTS

For the 45 kidney grafts rinsed and preserved with Eurocollins (strategy S1: n1 = 45) the cost/graft was estimated at 40 euros. With Viaspan (strategy S2: n2 = 61) the corresponding cost/graft was 424 euros. Logistic regression analysis showed that Viaspan was better than Eurocollins solution (ebeta = 0.437; P = 0.05) in preventing DGF. Overall, S2 was less expensive than S1, from the hospital's perspective. The mean difference per patient was 278 euros, which amounts to a saving of 2% of the total cost per renal transplantation. For rinsing and preserving kidney grafts Belzer solution is therefore preferable to Eurocollins solution.

摘要

目的

确定比欧科林溶液更昂贵的贝尔泽溶液(维司配能,百时美施贵宝公司,比利时布鲁塞尔)在预防移植肾功能延迟恢复(DGF)方面是否更优,以及其是否具有成本效益,因为它可能会减少移植后并发症。

方法

通过对1993年1月1日至1998年3月31日期间接受肾移植的106例患者进行调查,评估使用这两种冲洗和保存溶液相关并发症的发生风险。记录疗效和不良结局以及与医院环境中移植手术直接相关的费用:住院、冲洗和保存溶液、医疗和技术干预以及诊断检查。

结果

对于45个用欧科林溶液冲洗和保存的肾移植(策略S1:n1 = 45),每个移植的成本估计为40欧元。使用维司配能(策略S2:n2 = 61)时,每个移植的相应成本为424欧元。逻辑回归分析表明,在预防DGF方面,维司配能优于欧科林溶液(ebeta = 0.437;P = 0.05)。总体而言,从医院角度看,S2比S1成本更低。每位患者的平均差异为278欧元,相当于每次肾移植总成本节省2%。因此,对于冲洗和保存肾移植,贝尔泽溶液优于欧科林溶液。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验